Knoxville, Tenn. – (August 31, 2015) – EDP Biotech Corporation, (EDP), a global in vitro diagnostic innovator of simple, blood-based cancer diagnostic tests, announces the publication of key study data for its ColoMarkerÒ ELISA kit. In this clinical research study, ColoMarker demonstrated an overall sensitivity of 97.7% with specificity of 84.4% for all colorectal cancer detection and a nearly 100% sensitivity for early stage (I, II and III) colorectal cancer. Additionally, ColoMarker demonstrated 40% sensitivity to adenomatous polyps. ColoMarker received CE Mark approval as an aid in the detection of early stage colorectal cancer in late 2014.
Topics
Recent Posts
- Press Release: ColoHealth Blood Test Offers a Simpler First Step in Colorectal Cancer Screening–Now Direct-to-Consumer
- Hepion Pharmaceuticals, New Day Diagnostics execute binding letter of intent
- Press Release: Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC
- We’ve Been Busy, and the Press Has Noticed!
- Knoxville lab launches blood test for colorectal cancer screening across US: ‘Life mission’